期刊文献+

小剂量左西孟旦治疗老年重症急性左心衰竭的临床观察 被引量:9

Effects of small dose levosimendan in treatment of elderly patients with severe acute left heart failure
下载PDF
导出
摘要 目的通过与多巴酚丁胺比较,观察小剂量左西孟旦治疗老年重症急性左心衰竭的有效性。方法对26例老年重症急性左心衰竭患者使用了左西孟旦,25例患者使用多巴酚丁胺作为对照组,观察用药前后生命体征、呼吸困难程度评分、LVEF、SV、BNP和生化指标。结果两组用药前后生命体征比较,差异无统计学意义;两组用药后24 h呼吸困难程度评分降低,LVEF、SV升高、BNP浓度下降,与用药前比较有统计学差异(P<0.05),且实验组显著优于对照组(P<0.05);两组停药后24 h各项指标比较差异有统计学意义(P<0.05)。结论对老年重症急性左心衰竭患者推荐使用小剂量左西孟旦。 Objective To compare the efficacy of small dose levosimendan and dobutamine in plderly patient with severe acute left heart failure.Methods Acute left heart failure was treated with levosimendan in 26 elderly patients as trial group,and with dobutamine in 25 elderly patients as control group.Vital signs,dyspnea,LVEF,SV,BNP and blood biochemical index before and after drug administration were observed.Results There were no significant differences in vital signs between the trial group and the control group before and after drug administration(P〈0.05).Decrease of dyspnea,increase of LVEF,SV,and decrease of BNP were significantly different before and after drug administration(P〈0.05),There were significant differences in dyspnea,LVEF,SV and BNP between the trial group and the control group at 24 h after drug administration and termination of drug administration(P〈0.05).Conclusions Small dose levosimendan is recommended for treating elderly patients with severe acute left heart failure.
作者 朱海东
出处 《武警医学》 CAS 2013年第1期13-15,共3页 Medical Journal of the Chinese People's Armed Police Force
关键词 心力衰竭 充血性 左西孟旦 治疗结果 heart failure congestive levosimendan effect
  • 相关文献

参考文献7

二级参考文献102

  • 1吴杰,倪桑.缬沙坦治疗充血性心力衰竭疗效观察[J].中国心血管病研究,2004,2(8):643-644. 被引量:3
  • 2王小东,李培杰,杨兰,张彤哲,田学林,陈红纲.乌司他丁对心肺复苏后兔心脏保护作用的实验研究[J].中国急救医学,2007,27(5):436-439. 被引量:16
  • 3[1]Pollesello P,Papp Z.The cardioprotective effects of levo-simendan:preclinical and clinical evidence[J].J Cardio-vasc Pharmacol,2007,50 (3):257-263.
  • 4[2]Follath F,Cleland JG,Just H,et al.Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study):a ran-domized double-blind trial[J].Lancet,2002,360(9328):196-202.
  • 5[3]Lehtonen L,Poder P.The utility of levosimendan in the treatment of heart failure[J].Ann Med,2007,39 (1):2-17.
  • 6[4]Follath F,Franco F,Cardoso JS.European experience on the practical use of levosimendan in patient with acute heart failure syndromes[J].Am J Cardiol,2005,96(6A):80G-85G.
  • 7[5]Kyrzopoulos S,Adamopoulos S,Parissis JT,et al.Levo-simendan reduces plasma B-type natriuretic peptide and in-terleukin 6,and improves central hemodynamics in severe heart failure patients[J].Int J Cardiol,2005,99 (3):409-413.
  • 8[6]Franeo F,Monteiro P,Gonealves F,et al.Prognostic value of BNP changes in patients with decompensated advanced heart failure treated with levosimendan[abstraet][J].Cir-culation,2003,108(suppl 4):Ⅳ-447.
  • 9[7]Nanas JN,Papazoglou PP,Terrovitis JV,et al.Hemody-namic effects of levosimendan added to dobutamine in pa-tients with decompensated advanced heart failure refracto-ry to dobutamine aloneEJ1.Am J Cardiol,2004,94(10):1329-1332.
  • 10[8]Rokyta R Jr,Peehman V.The effects of Levosimendan on global haemodynamies in patients with cardiogenic shock[J].Neuro Endoerinol Lett,2006,27(1-2):121-127.

共引文献70

同被引文献76

  • 1张耀春,王彦,王立为.左西孟旦的药理、毒理学研究综述[J].中国药物应用与监测,2005,2(1):59-61. 被引量:20
  • 2陈桂荣,陈玉彬.新型钙增敏剂的研究进展[J].实用药物与临床,2006,9(2):123-125. 被引量:2
  • 3Brixius K , Reicke S , Schwinger RH , et al. Benificial effects of the Ca^2+ sensitizer levosinmendan in human myocardium[J]. Am J Physiol Heart Circ Physiol, 2002, 282(1) :131- 137.
  • 4Szilayi S,Pollesello P, Levijoki J, et al. The effects of levosimendan and OR-1896 on isolated hearts , myoeyte- sized preparations and phosphodiesterase enzymes of the guinea pig[J]. EurJ Pharmacol ,2004,486(1): 67-74.
  • 5Paraskevaids IA, Parissis JT. Anti inflammatory and an- ti apottotic effcets of levosimendan in decompensated heart failure: a novel mechanism of drug-induced im- proved in contractile performance of the failing heart [J]. Curr Med chem Cardiovasc Hematol Agents, 2005,3(3) : 243 -247.
  • 6Brixius K , Reicke S , Schwinger RH , et al. Benificial effects of the Ca^2+ sensitizer levosinmendan in human myocardium[J]. Am J Physiol Heart Circ Physiol, 2002, 282(1):131- 137.
  • 7Antila S,Jarvinen A, Honkanen T, et al. Pharmacokinet-ic and pharmacodynamic interaction between the novel calcium sensitiser levosimendan and warfarin [J]. Eur J Clin Pharmacol, 2000,56 ( 9 -- 10) : 705-710.
  • 8Matti D, Kivikko MD,Saila A,et al. Pharmacodynam- ics and safety of a new calcium sensitizer,levosimendan, and its metabolites during an extended infusion in patients with severe heart failure[J]. Clin Pharmacol, 2002,42 (1) :43- 51.
  • 9Follath F, Cleland JG, Just H,etal. Efficacy and safe- ty of intravenous levosimendan compared with dobu tamine in severe low output heart failure (the LIDO stud- y): a randomised double-blind trial[J]. Lancet, 2002, 360(9328) :196- 202.
  • 10Moiseyev VS, Poder P, Andrejevs N,et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myo- cardial infarctionA randomized, placebo-controlled, double-blind study (RUSSLAN) [J]. Eur Heart, 2002 ,23 (18) : 1422-1432.

引证文献9

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部